StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)

StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERVGet Rating) in a research note issued to investors on Monday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

A number of other research analysts have also issued reports on NERV. Zacks Investment Research upgraded shares of Minerva Neurosciences from a hold rating to a buy rating and set a $0.75 target price on the stock in a research report on Saturday, March 5th. HC Wainwright decreased their target price on shares of Minerva Neurosciences to $5.00 and set a buy rating on the stock in a research report on Friday, March 4th.

Shares of NERV stock opened at $0.76 on Monday. The firm’s 50-day moving average is $0.75 and its 200-day moving average is $1.00. The stock has a market cap of $32.30 million, a price-to-earnings ratio of -0.64 and a beta of 0.93. Minerva Neurosciences has a 52-week low of $0.63 and a 52-week high of $3.54.

Minerva Neurosciences (NASDAQ:NERVGet Rating) last announced its quarterly earnings results on Tuesday, March 1st. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.08. As a group, research analysts anticipate that Minerva Neurosciences will post -0.69 EPS for the current fiscal year.

Institutional investors have recently modified their holdings of the company. Two Sigma Securities LLC bought a new stake in shares of Minerva Neurosciences during the 3rd quarter worth approximately $29,000. GSA Capital Partners LLP lifted its holdings in shares of Minerva Neurosciences by 26.0% during the 3rd quarter. GSA Capital Partners LLP now owns 480,629 shares of the biopharmaceutical company’s stock worth $836,000 after acquiring an additional 99,141 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Minerva Neurosciences by 9.7% during the 3rd quarter. Geode Capital Management LLC now owns 488,813 shares of the biopharmaceutical company’s stock worth $850,000 after acquiring an additional 43,034 shares during the period. Millennium Management LLC lifted its holdings in shares of Minerva Neurosciences by 2.6% during the 4th quarter. Millennium Management LLC now owns 799,398 shares of the biopharmaceutical company’s stock worth $640,000 after acquiring an additional 19,977 shares during the period. Finally, BlackRock Inc. lifted its holdings in shares of Minerva Neurosciences by 3.7% during the 4th quarter. BlackRock Inc. now owns 506,457 shares of the biopharmaceutical company’s stock worth $406,000 after acquiring an additional 18,087 shares during the period. 55.03% of the stock is owned by institutional investors.

About Minerva Neurosciences (Get Rating)

Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease.

See Also

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.